Key Takeaways:
LAEKNA’s (2105.HK) positive Phase III results for its cancer drug afuresertib position it to challenge existing therapies in a heavily pre--treated breast cancer population, potentially unlocking a significant market. The successful outcome for the AKT inhibitor in patients with specific genetic alterations addresses a key area of unmet need in oncology.
"The combination therapy demonstrated a highly statistically significant and clinically meaningful improvement compared with the control group," the company said in its official announcement.
The pivotal AFFIRM-205 study enrolled 261 patients with HR+/HER2- locally advanced or metastatic breast cancer harboring PIK3CA/AKT1/PTEN alterations. The trial was designed to assess afuresertib in combination with fulvestrant against a placebo with fulvestrant. A significant majority of the subjects, 70.5%, had previously been treated with CDK4/6 inhibitors, a current standard of care, indicating the study targeted a difficult-to-treat population.
The successful data significantly de-risks a key asset in Laekna's pipeline and could pave the way for regulatory filings in major markets. For investors, this signals a potential future revenue stream for the Hong Kong-listed biotech, which has been focused on developing its oncology portfolio and now has a clear path forward for its lead candidate.
Afuresertib is a novel, potent, and highly selective small molecule inhibitor of the AKT kinase. The PI3K/AKT signaling pathway is frequently mutated in breast cancer, leading to tumor growth and resistance to endocrine therapies. By targeting AKT, Laekna's drug aims to overcome this resistance.
The trial's success in a population where over 70% of patients had already progressed after treatment with a CDK4/6 inhibitor like Pfizer's Ibrance or Eli Lilly's Verzenio is particularly noteworthy. This suggests afuresertib could be a viable next-line treatment option, a critical position in the lucrative oncology market. The positive progression-free survival (PFS) data, the study's primary endpoint, provides a strong basis for discussions with regulators.
The positive outcome increases the probability of future revenue from LAE002 and could attract new investors ahead of potential market launch. The company did not disclose specific data on the magnitude of the PFS benefit or detailed safety results, which will be presented at an upcoming medical conference.
This article is for informational purposes only and does not constitute investment advice.
